Last reviewed · How we verify
Curcumin-phosphatidylcholine
Curcumin-phosphatidylcholine is a Biologic drug developed by Henry Ford Health System. It is currently in Phase 1 development. Also known as: Tumeric.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Curcumin-phosphatidylcholine |
|---|---|
| Also known as | Tumeric |
| Sponsor | Henry Ford Health System |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder (PHASE1)
- Effect of Highly Bioavailable Curcumin on Subjective Tinnitus (NA)
- Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD) (NA)
- Curcumin for Pediatric Nonalcoholic Fatty Liver Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Curcumin-phosphatidylcholine CI brief — competitive landscape report
- Curcumin-phosphatidylcholine updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI
Frequently asked questions about Curcumin-phosphatidylcholine
What is Curcumin-phosphatidylcholine?
Who makes Curcumin-phosphatidylcholine?
Is Curcumin-phosphatidylcholine also known as anything else?
What development phase is Curcumin-phosphatidylcholine in?
Related
- Manufacturer: Henry Ford Health System — full pipeline
- Also known as: Tumeric
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing